Pembrolizumab: Cost-Effective for Recurrent, MSI-H Endometrial Cancer
Per-cycle, PLD cost $2509, bevacizumab cost $7585, and pembrolizumab cost $9026.
SGO 2018
Bevacizumab Plus Chemotherapy Prolongs PFS in Endometrial Cancer With p53 Null Status
p53 mutational status may be a viable strategy upon which to base the course of therapy.
Adjuvant Chemotherapy Non-Inferior to Chemoradiotherapy in Cervical Cancer
There were no significant differences in patterns of recurrence in the chemotherapy vs CCRT groups.
Uterine Re-Curettage May Not Affect Required Chemotherapy Courses in GTN
After the initial year of follow-up, 2 patients in the standard arm and 1 patient in the re-curettage arm had relapsed.
One-Quarter of Patients With Gynecologic Cancer Cannot Afford Medical Care
Nearly half of patients were denied insurance coverage for a recommended treatment.
Trastuzumab With Carboplatin, Paclitaxel Improves PFS in Uterine Serous Carcinoma
Toxicity was similar in both arms.
GTN: MTX With, Without Dactinomycin May Be Effective Option
Patients in the single-course MTX+ACTD arm had a 46.81% CR rate after initial therapy.
Gynecologic Abdominal Surgery: Liposomal Bupivacaine May Reduce Opioid Use
Researchers randomly assigned 120 patients to receive bupivacaine HCl or liposomal bupivacaine.
Indocyanine Green Improves Sentinel Node Detection in Uterine Malignancies
Overall, 257 vs 527 SLNs were detected by isosulfan blue vs ICG, respectively.
Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
There were no reported changes in pain scores after surgery.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in SGO 2018
Loading... 
Loading...